Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks

Ionis Pharmaceuticals CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies. Monia said the company has secured two FDA approvals this year and expects a third decision in October with partner GSK for a chronic hepatitis B treatment. The company’s recently approved products include TRYNGOLZA for severe hypertriglyceridemia and ZANVASTRO for Alexander disease.

Monia described TRYNGOLZA as the first meaningful treatment option for severe hypertriglyceridemia, or sHTG, and said the product’s June label expansion broadened its addressable population beyond familial chylomicronemia syndrome, or FCS. The FCS indication addresses an estimated 3,000 U.S. patients, while the broader sHTG population exceeds 3 million people in the U.S., according to Monia. Ionis adjusted TRYNGOLZA’s price following the expansion from a rare-disease level to one more suitable for a highly prevalent condition. Ionis continues to target more than $3 billion in U.S. peak annual product sales for TRYNGOLZA.

Monia said July and August were “very good months” for the launch, citing physician enthusiasm, incoming prescriptions and payer coverage obtained through medical-exception and prior-authorization processes. Initial prescribing has focused on patients at the greatest risk of acute pancreatitis, including people with triglyceride levels above 880 milligrams per deciliter or a history of acute pancreatitis. Monia said the company is also seeing prescriptions for patients with triglycerides in the 500-to-800 range who do not have such a history.

TRYNGOLZA offers monthly 50-milligram and 80-milligram dosing through an autoinjector. Monia said physicians are using both doses, with some starting patients at 50 milligrams and others using 80 milligrams initially. The company is emphasizing disease awareness, physician education, patient outreach, payer coverage and patient-support services to build the market. Monia cautioned investors against relying on third-party prescription data from Symphony and IQVIA to gauge the launch. Ionis blocks its data and now uses multiple specialty pharmacies, making comparisons with the prior FCS launch unreliable, he said. The company plans to provide additional details with its third-quarter earnings report.

On safety, Monia said TRYNGOLZA has a clean profile without required monitoring. He characterized liver-fat increases as small, on-target effects that declined toward baseline with continued treatment. The company studied approximately 250 patients using MRI, he said.